---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-050965"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:43:50.238229+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte increases ATM equity offering capacity from $150M to $400M

## Summary
- Amendment to Sales Agreement with Jefferies raises aggregate offering amount to $400M.
- As of Feb 27, 2023, ~$137.8M had been sold under the prior $150M ATM program.
- Material terms unchanged; sales made via at-the-market offerings on Nasdaq.
- Shares registered under existing shelf registration statement; no obligation to sell.

## SEC filing metadata
- accession: 0001193125-23-050965
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523050965/0001193125-23-050965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523050965/d448993d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-050965
- JSON: https://secwatch.observer/filing/0001193125-23-050965.json
- Plain text: https://secwatch.observer/filing/0001193125-23-050965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.